Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Erythropoietin counteracts breast cancer treatment with herceptin

16.11.2010
Researchers find erythropoiesis-stimulating drugs cut response to HER2 targeted therapy

Red-blood-cell-boosting drugs used to treat anemia may undermine breast cancer treatment with Herceptin, a targeted therapy that blocks the cancer-promoting HER2 protein, researchers from The University of Texas MD Anderson Cancer Center report in the Nov. 16 edition of Cancer Cell.

"Our research indicates when the two drugs were used at the same time, Herceptin was less effective," said study senior author Zhen Fan, M.D., associate professor in MD Anderson's Department of Experimental Therapeutics.

Natural erythropoietin (EPO) controls the body's red blood cell production. Manufactured versions called erythropoietin-stimulating agents or recombinant erythropoietin treat anemia caused by kidney failure and cancer treatment.

"Recombinant erythropoietin is a great drug, and it's saved many lives," Fan said. "Some studies, however, have shown that the drug has effects on cancer cells. We wanted to see if recombinant erythropoietin thwarts Herceptin, based on our understanding of how the two drugs work."

The researchers tested their hypothesis using breast cancer mouse models, then followed up with laboratory experiments on cancer cell lines to work out the molecular details. A retrospective case control study of 111 breast cancer patients supported their findings from the mouse studies.

Human epidermal growth factor receptor-2 (HER2) is overexpressed in 25-30 percent of breast cancers. The drug trastuzumab, known commercially as Herceptin, is an antibody designed to block HER2. Because resistance develops, only about a third of HER2-positive patients respond to the drug.

The presence of functional erythropoietin receptors on HER2-positive breast cancer could be one resistance mechanism, Fan said.

"The whole idea with targeted therapy against the HER2 protein is to shut off the downstream molecular activity launched by HER2," Fan said. "Erythropoietin can activate similar downstream pathways if its receptor is expressed on cancer cells, causing antagonism between the two drugs."

Fan and colleagues demonstrate that when erythropoietin connects with its receptor protein (EpoR), it launches a chain of events that activates Src, a crucial component of a pathway that trastuzumab blocks. It also shuts down a well-known tumor-suppressing gene called PTEN that is believed to be important to trastuzumab's activity against cancer cells.

There is controversy in academic circles about the role and function of EpoR in cancer cells and other types of cells not involved in blood production. It's important to note, Fan said, the team found no evidence that recombinant erythropoietin alone promotes cancer growth.

Tracking down the details

In three HER2-positive breast cancer cell lines, trastuzumab inhibited cell survival and proliferation, while recombinant erythropoietin stimulated cell survival and growth. When the three lines were treated together with trastuzumab and the anemia drug, cell survival increased from 58 percent to 80 percent, 57 percent to 77 percent, and 34 percent to 57.5 percent, respectively.

Two HER2-positive breast cancer cell types were introduced to mice, who then either received mock treatment, trastuzumab only, erythropoietin only or both drugs. Tumors treated with trastuzumab either shrank or stopped growing, with average tumor volume close to zero after 50 days in one cell line and barely registering in another. Growth of tumors treated with erythropoietin closely tracked the control group, increasing rapidly to an average volume of 1,500 cubic millimeters in one line and 600 mm3 in another. Tumors treated with both drugs grew more slowly to about 700 mm3 and 300 mm3.

Improved patient survival in small study

In a retrospective case-control study of patients with HER2-positive breast cancer that had spread, the team compared overall survival and progression-free survival between a group of 37 patients who received trastuzumab plus chemotherapy and recombinant erythropoietin to a matched control group of 74 whose cancer was treated the same way but who received no EPO.

A statistically significant difference in progression-free survival emerged at one year, with 40 percent of the control group having stable disease compared with 19 percent of the erythropoietin group. Overall progression-free survival differences across two years were not statistically significant.

The control group also had better overall survival than the erythropoietin group that was statistically significant in an analysis of multiple variables.

Fan emphasized that clinical findings should be interpreted with caution because the study was small and retrospective. Patients who received erythropoietin might have been sicker than the patients not treated with erythropoietin. Their findings need to be confirmed by larger clinical studies.

"We're expanding this study to include other types of cancer," Fan said. "Of course, different types of cancers are treated with different types of targeted therapies. We need to design our studies using different targeting agents than Herceptin to study whether erythropoietin can antagonize these drugs," Fan said.

Looking forward, Fan said, researchers need to find out why and how some cancer cells express the receptor protein for erythropoietin, and to what extent cancer cells express EpoR. "Recombinant erythropoietin helps to improve a patient's general condition without the need for a blood transfusion," Fan said. "If we can figure out how the expression of the erythropoietin receptor is regulated in cancer cells, we may come up with some new strategies to allow cancer patients to receive the drug for their anemia and fatigue without compromising their treatment with novel targeted therapies, such as anti-HER2 therapy with Herceptin."

The study was funded by a grant from the National Cancer Institute, research awards by the Breast Cancer Research Foundation, and by MD Anderson's Cancer Center Support Grant from from the NCI.

Co-authors with Fan, all from MD Anderson, are first author Ke Liang, Yang Lu, Xinqun Li, M.D., Ph.D., and John Mendelsohn, M.D., all of the department of Experimental Therapeutics; Francisco Esteva, M.D., Ph.D., Giampaolo Bianchini, M.D., Ching-Yi Yang and Gabriel Hortobagyi, M.D., all of the Department of Breast Medical Oncology; Yong Li, Ph.D., Constance Albarracin, M.D., Ph.D., of the Department of Pathology; Katherine Stemke-Hale, Ph.D., and Gordon Mills, M.D., Ph.D., of the Department of Systems Biology; and Chun-Te Chen and Mien-Chie Hung, M.D., Ph.D., of the Department of Molecular and Cellular Oncology.

Scott Merville | EurekAlert!
Further information:
http://www.mdanderson.org

More articles from Life Sciences:

nachricht Embryonic development: How do limbs develop from cells?
18.05.2018 | Humboldt-Universität zu Berlin

nachricht Reading histone modifications, an oncoprotein is modified in return
18.05.2018 | American Society for Biochemistry and Molecular Biology

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

Im Focus: Dozens of binaries from Milky Way's globular clusters could be detectable by LISA

Next-generation gravitational wave detector in space will complement LIGO on Earth

The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...

Im Focus: Entangled atoms shine in unison

A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.

The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...

Im Focus: Computer-Designed Customized Regenerative Heart Valves

Cardiovascular tissue engineering aims to treat heart disease with prostheses that grow and regenerate. Now, researchers from the University of Zurich, the Technical University Eindhoven and the Charité Berlin have successfully implanted regenerative heart valves, designed with the aid of computer simulations, into sheep for the first time.

Producing living tissue or organs based on human cells is one of the main research fields in regenerative medicine. Tissue engineering, which involves growing...

Im Focus: Light-induced superconductivity under high pressure

A team of scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg investigated optically-induced superconductivity in the alkali-doped fulleride K3C60under high external pressures. This study allowed, on one hand, to uniquely assess the nature of the transient state as a superconducting phase. In addition, it unveiled the possibility to induce superconductivity in K3C60 at temperatures far above the -170 degrees Celsius hypothesized previously, and rather all the way to room temperature. The paper by Cantaluppi et al has been published in Nature Physics.

Unlike ordinary metals, superconductors have the unique capability of transporting electrical currents without any loss. Nowadays, their technological...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

 
Latest News

Supersonic waves may help electronics beat the heat

18.05.2018 | Power and Electrical Engineering

Keeping a Close Eye on Ice Loss

18.05.2018 | Information Technology

CrowdWater: An App for Flood Research

18.05.2018 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>